Cisplatin and ckd
WebApr 11, 2024 · The poster shows the final data from a phase 2 study evaluating the ability of the DRP ® companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that ... Weberdafitinib increases levels of cisplatin by decreasing renal clearance. Modify Therapy/Monitor Closely. Consider alternatives that are not OCT2 substrates or consider …
Cisplatin and ckd
Did you know?
WebApr 14, 2024 · Among the extracellular vesicles, apoptotic bodies (ABs) are only formed during the apoptosis and perform a relevant role in the pathogenesis of different diseases. Recently, it has been demonstrated that ABs from human renal proximal tubular HK-2 cells, either induced by cisplatin or by UV light, can lead to further apoptotic death in … WebMar 13, 2024 · Background. Cisplatin (cis-diamminedichloroplatinum II, CDDP) is one of the most effective chemotherapeutic agents. However, its clinical use is limited due to the …
WebThe U.S. Food and Drug Administration granted cisplatin approval in treating testicular and ovarian cancer in 1978 ( Basu and Krishnamurthy, 2010 ). Now, Cisplatin is still widely used to treat a variety of solid tumors including bladder cancer, head and neck cancer, esophageal cancer, and so on. WebApr 1, 2024 · Cisplatin is a potent and widely used chemotherapy drug for cancer treatment, but is notorious for adverse effects in normal tissues and organs, especially in the kidneys. Over a quarter of patients with cancer develop kidney problems during or after cisplatin chemotherapy.
WebDec 17, 2024 · In cisplatin-induced acute kidney injury (AKI) or nephrotoxicity, autophagy is rapidly induced in renal tubular epithelial cells and acts as a cytoprotective mechanism for cell survival. Both mTOR … WebDec 12, 2024 · Repetitive administration of cisplatin could cause subclinical kidney injury, which over time, leads to chronic kidney disease. This hypothesis was studied on animal …
WebApr 14, 2024 · Among the extracellular vesicles, apoptotic bodies (ABs) are only formed during the apoptosis and perform a relevant role in the pathogenesis of different …
WebNational Center for Biotechnology Information nifty stopwatchnpat acronymNational Center for Biotechnology Information npat application formWebMar 15, 2016 · Patients with risk factors for CKD may have a higher incidence of cisplatin-induced nephrotoxicity. Indeed, acute kidney injury (AKI) is more frequently observed in patients with CKD [ 7, 8 ]. Furthermore, recent studies have reported that patients with lung cancer have a higher incidence of comorbidities than do patients with other cancers [ 9 ]. nifty stock weightage 2023WebMar 1, 2024 · Acute kidney injury (AKI) is the main obstacle that limits the use of cisplatin in cancer treatment. Proton pump inhibitors (PPIs), the most commonly used class of medications for gastrointestinal complications in cancer patients, have been reported to cause adverse renal events. However, the effect of PPIs on cisplatin-induced AKI … nifty stopwatch questWebApr 11, 2024 · The poster shows the final data from a phase 2 study evaluating the ability of the DRP ® companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that are likely to respond to treatment with LiPlaCis ®, a targeted liposomal formulation of cisplatin. nifty stocks with weightageWebAbstract Acute kidney injury (AKI) is a common clinical problem, and patients who survive AKI have a high risk of chronic kidney disease (CKD). The mechanism of CKD post-AKI, characterized by progressive renal fibrosis, is still unclear. Maladaptive tubular epithelial cells (TECs) after AKI are considered a leading cause of renal fibrosis post-AKI. nifty stopwatch mats